Karuna Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Karuna Therapeutics Inc (KRTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Karuna Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 11M vs 110,740M combined for its competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $1.13M compares with $1.82M for the peer group (0.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Karuna Therapeutics Inc vs. its Competitors, Q3 2023
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Karuna Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Karuna Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Karuna Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (95) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Karuna Therapeutics Inc's competitor groups requires a Commercial License.
Karuna Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Karuna Therapeutics Inc | - | - | - | No |
| Competitors combined (42) | ||||
| High-Confidence Competitors (104) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KRTX Stock Performance relative to its Competitors
KRTX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Climb Bio Inc | 282.9% | Outperformed |
| 2 | Gossamer Bio Inc | 282.9% | Outperformed |
| 3 | Oscar Health Inc | 282.9% | Outperformed |
| 4 | Amylyx Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Ovid Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Karuna Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Karuna Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Karuna Therapeutics Inc |
12,190.19 | 11.29 |
 Eli Lilly And Company |
1,221,912.11 | 86,462.00 |
 Intra cellular Therapies Inc |
13,599.88 | 680.85 |
 Oscar Health Inc |
11,063.27 | 15,318.63 |
 Biomarin Pharmaceutical Inc |
10,864.27 | 3,655.13 |
 Cerevel Therapeutics Holdings Inc |
8,165.22 | 0.00 |
| SUBTOTAL | 1,319,879.13 | 113,505.36 |
Sign in to see all competitors of Karuna Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Karuna Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Karuna Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Karuna Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Corvus Pharmaceuticals, Inc. | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Fulgent Genetics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Scinai Immunotherapeutics Ltd | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Tc Biopharm holdings Plc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Exscientia Plc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Eisai Co., Ltd. | Company report | 85% |
| Atreca inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Tango Therapeutics, Inc. | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Exelixis, Inc. | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Astellas Pharma Inc. | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Syndax, Inc. | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Replimune Group Inc | Company report | 85% |
| BMS | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Boehringer Ingelheim AG | Company report | 85% |
| RENB | Company report | 85% |
| Bayer-Schering Pharmaceutical | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| APDN | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Perspective Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Biomarin Pharmaceutical Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Harpoon Therapeutics Inc | Company report | 85% |
| Longboard Pharmaceuticals Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
| Ideaya Biosciences Inc | Company report | 85% |
| Aldeyra Therapeutics Inc | Company report | 85% |
| Cogent Biosciences Inc | Company report | 85% |
| Prelude Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Ovid Therapeutics Inc | Company report | 85% |
| Repare Therapeutics Inc | Company report | 85% |
| Xilio Therapeutics Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Prothena Corporation Public Limited Company | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Celldex Therapeutics inc | Company report | 85% |
| Reunion Neuroscience Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Merus N v | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Karuna Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Karuna Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Alkermes Plc | Single Reporting Segment 100.00 % |
| Acadia Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Gossamer Bio Inc | Reporting 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Karuna Therapeutics Inc .
Karuna Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Karuna Therapeutics Inc | 12,190 | 1,129,100 | -43,368,000 |
| Eli Lilly And Company | 1,221,912 | 1,729,240 | 551,594 |
| Intra cellular Therapies Inc | 13,600 | 3,370,554 | -369,683 |
| Oscar Health Inc | 11,063 | 6,645,828 | 239,016 |
| Biomarin Pharmaceutical Inc | 10,864 | 1,134,780 | -5,934 |
| Cerevel Therapeutics Holdings Inc | 8,165 | 0 | -1,771,031 |
| PEERS TOTAL | 1,307,689 | 1,820,332 | 404,826 |
Sign in to see all peers for Karuna Therapeutics Inc .
Karuna Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Karuna Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 5.2x | 4.3x | +1.0x |
| Return on Equity | -31.63 % | industry aggregate | -44.86 % |
| Return on Invested Capital | -17.99 % | -9.88 % (avg) | -8.11 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Karuna Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | - | -9.86 % | -13.23 % | -18.23 % | -17.99 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Karuna Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 44.9 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (70.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-54.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Karuna Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Karuna Therapeutics Inc | 6.61 | 31.17 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Intra cellular Therapies Inc | 2.40 | 6.78 | - |
| Oscar Health Inc | 0.66 | 0.98 | 0.35 |
| Biomarin Pharmaceutical Inc | 1.07 | 3.41 | 0.47 |
| Cerevel Therapeutics Holdings Inc | 3.33 | 10.31 | 0.91 |
Sign in to see all peers for Karuna Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Karuna Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Karuna Therapeutics Inc | Q3 2023 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Intra cellular Therapies Inc | Q4 2024 | +50.8 % | - |
| Oscar Health Inc | Q2 2026 | +70.4 % | - |
| Biomarin Pharmaceutical Inc | Q3 2026 | +32.0 % | - |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | - |
| PEERS TOTAL | +41.9 % | +29.2 % |
Sign in to see all peers for Karuna Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Karuna Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Karuna Therapeutics Inc | Q3 2023 | - | +175.5 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Intra cellular Therapies Inc | Q4 2024 | - | - |
| Oscar Health Inc | Q2 2026 | - | +26.8 % |
| Biomarin Pharmaceutical Inc | Q3 2026 | +46.6 % | -18.9 % |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | -19.3 % |
Sign in to see all peers for Karuna Therapeutics Inc .
Karuna Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Karuna Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Intra cellular Therapies Inc | - | - | - |
| Oscar Health Inc | 6.76% | 27.79% | 38.46% |
| Biomarin Pharmaceutical Inc | - | - | - |
| Cerevel Therapeutics Holdings Inc | - | - | - |
Sign in to see all peers for Karuna Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Karuna Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Karuna Therapeutics Inc | - | 1,079.64 |
| Eli Lilly And Company | 44.41 | 14.13 |
| Intra cellular Therapies Inc | - | 19.97 |
| Oscar Health Inc | 25.92 | 0.72 |
| Biomarin Pharmaceutical Inc | - | 2.97 |
| Cerevel Therapeutics Holdings Inc | - | - |
| PEERS AVERAGE | 53.21 | 11.63 |
Sign in to see all peers for Karuna Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.